Noticewala SS, Mell LK, Olson SE, Read W. Survival in unresectable sinonasal undifferentiated carcinoma treated with concurrent intra-arterial cisplatin and radiation. World J Clin Cases 2015; 3(2): 191-195 [PMID: 25685767 DOI: 10.12998/wjcc.v3.i2.191]
Corresponding Author of This Article
William Read, MD, Associate Professor of Hematology and Medical Oncology, Emory University, 550 Peachtree St NE, MOT 18, Atlanta, GA 30308, United States. william.l.read@emory.edu
Research Domain of This Article
Oncology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Feb 16, 2015; 3(2): 191-195 Published online Feb 16, 2015. doi: 10.12998/wjcc.v3.i2.191
Survival in unresectable sinonasal undifferentiated carcinoma treated with concurrent intra-arterial cisplatin and radiation
Sonal S Noticewala, Loren K Mell, Scott E Olson, William Read
Sonal S Noticewala, Loren K Mell, Department of Radiation Medicine and Applied Sciences, Center for Advanced Radiotherapy Technologies, University of California San Diego, La Jolla, CA 92093, United States
Scott E Olson, Division of Neurosurgery, University of California San Diego, La Jolla, CA 92103, United States
William Read, Department of Hematology and Medical Oncology, Emory University, Atlanta, GA 30308, United States
Author contributions: Noticewala SS co-wrote manuscript, involved in literature review of SNUC, and performed patient chart review; Mell LK co-wrote manuscript, involved in patient care, involved in literature review of SNUC, provided images; Olson SE involved in patient care, provided images, co-wrote manuscript; Read W co-wrote manuscript, involved in patient care, involved in literature review of SNUC.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: William Read, MD, Associate Professor of Hematology and Medical Oncology, Emory University, 550 Peachtree St NE, MOT 18, Atlanta, GA 30308, United States. william.l.read@emory.edu
Telephone: +1-404-7781900 Fax: +1-404-6864604
Received: July 28, 2014 Peer-review started: July 28, 2014 First decision: September 28, 2014 Revised: November 4, 2014 Accepted: November 17, 2014 Article in press: November 19, 2014 Published online: February 16, 2015 Processing time: 192 Days and 6.1 Hours
Abstract
We report the successful use of RADPLAT to treat a patient with an unresectable T4N0 sinonasal undifferentiated carcinoma. This patient received 4 cycles of weekly intra-arterial cisplatin together with thiosulfate infusion with concurrent radiation therapy. Radiation therapy was given in 28 daily fractions to 54 Gy using intensity-modulated radiation therapy followed by a hypofractionated stereotactic boost of 3 fractions to 13 Gy to a total dose of 67 Gy in 31 fractions to the nasal sinus and bilateral neck. Intra-arterial cisplatin was administered using a bilateral approach due to the midline site of this tumor. Within days of the first intra-arterial cisplatin, there was an obvious decrease in tumor size. She has been followed with magnetic resonance imaging and positron emission tomography, and remains disease-free 47 mo post-treatment. Centers with expertise in intra-arterial chemotherapy could consider the RADPLAT approach for patients with unresectable sinonasal undifferentiated carcinoma.
Core tip: Our patient with unresectable sinonasal undifferentiated carcinoma has enjoyed nearly 4 years disease-free survival after concurrent intra-arterial cisplatin and radiation.
